InterMune Stock Hits New 52-Week Low (ITMN)

NEW YORK ( TheStreet) -- InterMune (Nasdaq: ITMN) hit a new 52-week low Friday as it is currently trading at $10.56, below its previous 52-week low of $10.67 with 1.2 million shares traded as of 9:45 a.m. ET. Average volume has been 1.9 million shares over the past 30 days.

InterMune has a market cap of $803 million and is part of the health care sector and drugs industry. Shares are down 1.2% year to date as of the close of trading on Thursday.

InterMune, Inc., a biotechnology company, engages in the research, development, and commercialization of therapies in pulmonology and orphan fibrotic diseases. The company focuses on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.

TheStreet Ratings rates InterMune as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally weak debt management. You can view the full InterMune Ratings Report.

See all 52-week low stocks or get investment ideas from our investment research center.
null

If you liked this article you might like

Week in Review: Trump Rally Fizzles but Stocks End 2016 With Big Gains

Post-Trump Rally Stalls as Dow Jones Slips Further From 20,000 Mark

Stocks Slump Continues With All S&P 500 Sectors in Negative Territory

Hacking Case Shows Mounting Risk for M&A Law Firms, Corporate Clients

Stocks Turn Negative, Prolonging Dow's Trek Toward 20,000